Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Glaxosmithkline
Dostarlimab is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1-mediated suppression of anti-tumor immunity. It is studied in cervical cancer, advanced cancer and ovarian clear cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 2, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06065462 | Phase 1/2 | Ovarian Clear Cell Carcinoma | Recruiting | GSK |
| NCT03833479 | Phase 2 | Cervical Cancer | Active not recruiting | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerCervical CancerOvarian Clear Cell Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →